2
Clinical Trials associated with CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells(Second Affiliated Hospital of Guangzhou Medical University)A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung Cancer
This study is a clinical study on the safety, efficacy and I phase of single center, single arm, open-dose climbing, intravenous infusion of Anti- Epidermal growth factor receptor(EGFR) Chimeric Antigen Receptor(CAR) T cells modified by C-X-C Chemokine receptor type 5(CXCR 5) in patients with advanced adult non-small cell lung cancer(NSCLC).
A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung Cancer
This study is a single arm, open-label, intravenous infusion of Anti- Epidermal growth factor receptor (EGFR) Chimeric Antigen Receptor (CAR) T cells modified by C-X-C Chemokine receptor type 5 (CXCR 5) in patients with advanced adult non-small cell lung cancer (NSCLC).
100 Clinical Results associated with CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells(Second Affiliated Hospital of Guangzhou Medical University)
100 Translational Medicine associated with CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells(Second Affiliated Hospital of Guangzhou Medical University)
100 Patents (Medical) associated with CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells(Second Affiliated Hospital of Guangzhou Medical University)
100 Deals associated with CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells(Second Affiliated Hospital of Guangzhou Medical University)